Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics, Inc. (SAGE) Healthcare & Pipeline Overview

Sage Therapeutics, Inc. is a biopharmaceutical company specializing in central nervous system (CNS) disorders, with a portfolio including ZULRESSO for postpartum depression and zuranolone in Phase III trials for multiple depressive and anxiety conditions. The company leverages strategic collaborations to advance its pipeline, targeting significant unmet medical needs within neuroscience.

What Is the Investment Thesis for SAGE?

Sage Therapeutics, Inc. presents an investment profile centered on its specialized focus on central nervous system disorders and a pipeline of novel therapeutic candidates. Key value drivers include the commercialized product ZULRESSO for postpartum depression and the advanced-stage zuranolone, which is in Phase III trials for multiple high-prevalence conditions such as major depressive disorder, generalized anxiety disorder, and bipolar depression. The company's strategic collaborations with Biogen and Shionogi are critical for shared development costs and expanded market access, particularly for zuranolone. With a gross margin of 96.4%, Sage demonstrates strong profitability on its existing commercial product, though its overall profit margin of -354.7% reflects substantial ongoing investment in research and development for its pipeline. Growth catalysts are primarily tied to successful clinical trial outcomes and regulatory approvals for zuranolone across its various indications, which could unlock significant market potential. Further advancements of SAGE-324 for essential tremor and SAGE-718 for cognitive disorders also represent future value inflection points. Risks include the inherent uncertainties of drug development, potential clinical trial failures, regulatory delays, and intense competition within the biotechnology sector, alongside the need for sustained funding given its current unprofitability.

Based on FMP financials and quantitative analysis

SAGE Key Highlights

• Market Capitalization: $0.54 billion, reflecting its current valuation as a biopharmaceutical company with a pipeline in development.
• Gross Margin: 96.4%, indicating strong profitability on its commercialized product, ZULRESSO, before significant operating expenses.
• Profit Margin: -354.7%, underscoring substantial investment in research and development and clinical trials across its extensive pipeline.
• Employee Count: 353 employees, supporting its specialized focus on central nervous system disorder drug development and commercialization.
• Strategic Collaborations: Partnerships with Biogen MA Inc. and Shionogi & Co., Ltd. for co-development and commercialization of key pipeline assets like zuranolone and SAGE-324.

Who Are SAGE's Competitors?

SAGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SAGE's Key Strengths?

• Commercialized product ZULRESSO for postpartum depression provides an existing revenue stream and market presence.
• Diverse pipeline targeting multiple CNS disorders (PPD, MDD, GAD, essential tremor, cognitive disorders) reduces single-asset dependency.
• Strategic collaborations with Biogen and Shionogi provide shared resources, expertise, and expanded market access.
• High gross margin of 96.4% on its commercial product indicates strong unit economics before operating expenses.

What Are SAGE's Weaknesses?

• Significant negative profit margin of -354.7%, indicating substantial operational losses and reliance on continued financing.
• Reliance on successful clinical trial outcomes and regulatory approvals for pipeline assets, which are inherently uncertain.
• ZULRESSO's intravenous administration may limit broader market adoption compared to potential oral alternatives.
• Relatively small market capitalization ($0.54B) compared to larger pharmaceutical companies, potentially limiting R&D scale and competitive leverage.

What Could Drive SAGE Stock Higher?

• Potential regulatory decisions for zuranolone in major depressive disorder and postpartum depression, following the completion of its Phase III clinical trials.
• Advancement of SAGE-324 into Phase III clinical trials for essential tremor, signaling progress in a new therapeutic area and expanding the company's pipeline diversity.
• Initiation of later-stage clinical trials for SAGE-718 in cognitive disorders such as Huntington's or Alzheimer's disease, which could significantly broaden the pipeline's scope and market potential.
• Continued commercialization efforts for ZULRESSO, aiming to expand market penetration and patient access for postpartum depression treatment.
• Progress in strategic collaborations with Biogen and Shionogi, potentially leading to milestone payments or expanded development activities for key pipeline assets.

What Are the Key Risks for SAGE?

• Financial-distress signal — its Altman Z-Score of -5.33 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-28.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin of -354.7%, indicating substantial operational losses and a continued reliance on external financing to fund extensive research and development activities.
• Clinical trial failures or unexpected safety issues for pipeline candidates like zuranolone, SAGE-324, or SAGE-718, which could lead to development halts, asset write-downs, and a negative impact on future revenue prospects.
• Delays in regulatory approvals for zuranolone or other pipeline assets, which would extend the time to market, increase development costs, and postpone potential revenue generation.
• Intense competition within the central nervous system disorder market from larger, more established pharmaceutical companies with greater resources and broader product portfolios.
• Challenges in commercializing new products, including market access, securing favorable payer reimbursement, and achieving widespread physician adoption, even after regulatory approval.

What Are the Growth Opportunities for SAGE?

• Growth opportunity 1: Zuranolone for Major Depressive Disorder (MDD) and Postpartum Depression (PPD): Zuranolone is in Phase III clinical trials for multiple indications, including MDD and PPD. The global antidepressant market, which includes MDD treatments, was valued at approximately $15.6 billion in 2023 and is projected to grow. For PPD, zuranolone offers a potential oral, rapid-acting treatment, addressing a significant unmet need for accessible and effective therapies beyond ZULRESSO's intravenous administration. Successful regulatory approval and commercialization could unlock substantial market share, particularly given the large patient populations in these areas, potentially offering a more convenient treatment option for patients.
• Growth opportunity 2: Expansion into Generalized Anxiety Disorder (GAD) and Bipolar Depression: Zuranolone is also undergoing Phase III trials for GAD and bipolar depression. The global anxiolytic market is substantial, and effective treatments for bipolar depression are highly sought after. If approved, zuranolone could provide a novel therapeutic option, differentiating itself from existing treatments with its unique mechanism of action as a neuroactive steroid. This broadens Sage's potential market reach within CNS disorders, leveraging a single asset across multiple high-prevalence conditions and diversifying its revenue streams beyond its initial PPD focus.
• Growth opportunity 3: SAGE-324 for Essential Tremor: SAGE-324 is currently in Phase II clinical trials for essential tremor, a common neurological movement disorder. The global essential tremor treatment market is expected to grow, driven by an aging population and increasing diagnosis rates. With limited effective pharmacological options currently available, a successful development and commercialization of SAGE-324 could position Sage as a key player in this niche but significant market. Its advancement through trials represents a diversification of Sage's pipeline beyond mood disorders, tapping into a different neurological segment with distinct patient needs.
• Growth opportunity 4: SAGE-718 for Cognitive Disorders (Huntington's, Alzheimer's, ADHD): SAGE-718, an NMDA receptor modulator, has completed Phase I trials and targets a range of cognitive disorders including Huntington's disease, Alzheimer's disease, and ADHD. These represent massive, underserved markets with high unmet medical needs and significant patient populations. The global market for Alzheimer's disease therapeutics alone is projected to reach tens of billions of dollars. Successful progression of SAGE-718 through later-stage trials could unlock substantial long-term growth potential for Sage, offering novel approaches to complex neurological conditions with potentially transformative impact for patients.
• Growth opportunity 5: Strategic Collaborations with Biogen and Shionogi: Sage's partnerships with Biogen MA Inc. and Shionogi & Co., Ltd. provide significant growth opportunities. The collaboration with Biogen for zuranolone and SAGE-324 offers shared development costs, broader commercial reach, and leverages Biogen's expertise in neurology. The Shionogi partnership for zuranolone in Japan, Taiwan, and South Korea expands Sage's geographic footprint into key Asian markets, providing access to new patient populations and revenue streams without requiring extensive direct market entry infrastructure, thereby accelerating global market penetration.

What Opportunities Does SAGE Have?

• Potential market expansion with zuranolone's approval for MDD, GAD, and bipolar depression, addressing large patient populations.
• Advancement of SAGE-324 into later-stage trials for essential tremor, a condition with significant unmet medical needs.
• Development of SAGE-718 for major neurodegenerative and cognitive disorders like Alzheimer's and Huntington's, targeting massive markets.
• Leveraging partnerships to accelerate development and commercialization in new geographic markets, such as Asia with Shionogi.

What Threats Does SAGE Face?

• Clinical trial failures or unexpected safety concerns for pipeline candidates, which could halt development and impact future revenue.
• Regulatory hurdles or delays in obtaining marketing approvals for key assets like zuranolone, extending time to market and increasing costs.
• Intense competition from larger pharmaceutical companies developing CNS therapies with greater financial and commercial resources.
• Potential for patent expirations or market entry of generic/biosimilar alternatives for ZULRESSO in the long term.
• Challenges in securing adequate funding to sustain extensive R&D efforts given the company's current unprofitability.

What Are SAGE's Competitive Advantages?

• Proprietary pipeline of novel compounds targeting CNS disorders with unique mechanisms of action, such as neuroactive steroids and NMDA receptor modulators.
• Existing commercial product, ZULRESSO, providing a foundational revenue stream and established market presence in the treatment of postpartum depression.
• Strategic collaborations with established pharmaceutical companies like Biogen and Shionogi, leveraging their resources, expertise, and market access for pipeline assets.
• Extensive clinical trial data and regulatory expertise in navigating the complex approval processes for CNS therapeutics.
• Focus on areas with high unmet medical needs, potentially leading to faster regulatory pathways and strong market adoption upon approval.

What Does SAGE Do?

Sage Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for central nervous system (CNS) disorders. Incorporated in 2010 as Sterogen Biopharma, Inc., the company rebranded to Sage Therapeutics, Inc. in September 2011 and is headquartered in Cambridge, Massachusetts. The company's foundational product is ZULRESSO (brexanolone), an intravenous formulation approved for the treatment of postpartum depression (PPD) in adults, representing its initial commercialized therapy. Beyond ZULRESSO, Sage maintains a robust and diversified pipeline of product candidates. A key asset is zuranolone, a neuroactive steroid currently undergoing Phase III clinical trials for a broad range of indications, including PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression. This oral compound is a cornerstone of Sage's future growth strategy, aiming to provide more accessible treatment options for widespread psychiatric conditions. Further diversifying its therapeutic scope, Sage is developing SAGE-324, a compound in Phase II clinical trials for essential tremors, with completed Phase I trials for epilepsy and Parkinson's diseases. Additionally, the company's pipeline includes SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trials for various conditions such as depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. To support its extensive development efforts and expand its market reach, Sage has established strategic collaborations, including a partnership with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea, and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. These alliances are crucial for sharing development costs, leveraging partner expertise, and accessing international markets, positioning Sage to address significant unmet medical needs across various CNS disorders.

What Products and Services Does SAGE Offer?

• Develop and commercialize medicines for central nervous system (CNS) disorders.
• Market ZULRESSO, an intravenous treatment approved for postpartum depression (PPD).
• Advance zuranolone, an oral neuroactive steroid, through Phase III trials for PPD, major depressive disorder, generalized anxiety disorder, and bipolar depression.
• Conduct Phase II clinical trials for SAGE-324 to treat essential tremors, with prior Phase I trials for epilepsy and Parkinson's diseases.
• Explore SAGE-718, an NMDA receptor modulator, for cognitive disorders like Huntington's, Alzheimer's disease, and ADHD, having completed Phase I trials.
• Engage in strategic collaborations with pharmaceutical partners like Biogen and Shionogi for co-development and commercialization of pipeline assets.
• Focus on innovative mechanisms of action to address significant unmet needs in neurological and psychiatric conditions.

How Does SAGE Make Money?

• Commercialization of approved pharmaceutical products, such as ZULRESSO, through direct sales to healthcare providers and institutions.
• Potential future revenue streams from the commercialization of pipeline candidates like zuranolone and SAGE-324, upon successful regulatory approval and market launch.
• Receiving milestone payments and royalties from strategic collaboration agreements, such as those with Biogen and Shionogi, for the development and commercialization of their drug candidates in specific territories.
• Funding ongoing research and development efforts through equity financing and strategic partnership agreements to advance its drug pipeline.

What Industry Does SAGE Operate In?

Sage Therapeutics operates within the Biotechnology industry, specifically targeting the vast and complex landscape of central nervous system (CNS) disorders. This sector is characterized by high research and development costs, lengthy clinical trial processes, and significant unmet medical needs across conditions like depression, anxiety, and neurodegenerative diseases. Market trends indicate a growing demand for novel, effective, and well-tolerated therapies for CNS disorders, driven by increasing prevalence rates and an aging global population. Sage's focus on neuroactive steroids and NMDA receptor modulators positions it within an innovative segment of the industry, seeking to differentiate from conventional treatments. The competitive landscape includes numerous large pharmaceutical companies and smaller biotechs, all vying for market share with their own pipelines. Sage's strategy involves addressing specific indications with high unmet needs, such as postpartum depression with ZULRESSO, and broader conditions like major depressive disorder with zuranolone, leveraging its specialized scientific expertise.

Who Are SAGE's Key Customers?

• Patients diagnosed with central nervous system disorders, including postpartum depression, major depressive disorder, generalized anxiety disorder, essential tremor, and neurodegenerative conditions.
• Healthcare providers, including psychiatrists, neurologists, and other specialists who prescribe treatments for CNS disorders.
• Hospitals and specialized treatment centers that administer ZULRESSO for postpartum depression.
• Pharmaceutical partners like Biogen and Shionogi, who collaborate on development and commercialization of specific drug candidates.

Company Profile

Sage Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Barry E. Greene. SAGE has traded publicly since 2014.

How Sage Therapeutics, Inc. Is Valued

Sage Therapeutics, Inc. carries a market capitalization of 545M, placing it in the small-cap category. Relative to its peer group, SAGE's quantitative score of 51/100 is below the peer average of 76/100.

ROE -29%Key Financial Metrics

Return on equity for Sage Therapeutics, Inc. stands at -28.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -25.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Sage Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.33 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Sage Therapeutics, Inc. revenue of about $120.7M for fiscal 2026, with EPS near $-2.70. The estimate reflects 11 contributing analysts.

Net sellingInsider Activity

The most recent 12 insider filings for Sage Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 257K shares disposed (about $1.3M), a signal worth weighing alongside the fundamentals.

SAGE Financials

SAGE Latest News

SAGE Analyst Consensus

SAGE MoonshotScore

Common Questions About SAGE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources